Necitumumab is approved for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC); it functions as an anti-EGFR monoclonal antibody that inhibits epidermal growth factor receptor (EGFR) signaling, thereby suppressing tumor progression, angiogenesis, and anti-apoptotic pathways, ultimately leading to cancer cell death.